Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Proximagen Raises £50M Through Placing To Acquire, Develop Drug Programs
Proximagen has announced that it has conditionally placed 35714286 new ordinary shares of 1p each at a price of 140 pence per share, to raise gross proceeds of
Proximagen has announced that it has conditionally placed 35714286 new ordinary shares of 1p each at a price of 140 pence per share, to raise gross proceeds of
The World Health Organisation (WHO) has awarded global prequalification to GlaxoSmithKline’s vaccine against rotavirus, Rotarix. As part of an innovative ‘South-first’ access strategy, GSK Biologicals launched Rotarix in
Magellan Health Services has signed a definitive agreement to acquire First Health Services Corporation, a subsidiary of Coventry Health Care, which provides pharmacy benefits administration and other services
Merck has announced the results for the pivotal phase-III study of rolofylline (MK-7418), the investigational medicine for the treatment of acute heart failure. The results showed that rolofylline
Neuralstem has received a patent allowance from the US Patent and Trademark Office (USPTO) for several compounds that can help grow new neurons. Patent application 12/049,922, entitled Use
Wyeth has received positive recommendations from the European Committee for Medicinal Products for Human Use (CHMP) for two recent submissions relating to Enbrel (etanercept). It’s a tumour necrosis
Viro announced that it has received a Complete Response letter from FDA related to its supplemental Biologics License Application (sBLA) for Cinryze as a treatment for acute attacks
Lpath has been awarded a $3 million grant by the National Cancer Institute (NCI). The funds will support the continued clinical development of Lpath’s drug candidate, ASONEP, which
Asymchem has declared the issuance of a manufacturing certificate for drug products to its Tianjin 2 site, by the Tianjin branch of the Chinese State Food and Drug
XTENT has announced that it has received conditional approval from FDA for IDE, authorizing it to begin its pivotal clinical program, composed of two trials called Custom IV